In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals in Depth: November 2010

Executive Summary

Surprisingly no Big Pharmas or top biotech companies were party to the biggest alliances. Instead German drug maker Grunenthal won out, selling its oral contraceptives portfolio to Gedeon Richter for $331 million. Both valued at $800 million, Lilly's acquisition of Avid ($300 million up front plus $500 million in earn-outs) and Medtronic's takeover of Ardian tied for the top spots in the M&A category. FOPOs were the most lucrative vehicle in pharma and device fundraising, with each industry bringing in over $200 million from this financing type.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts